KELLY SUCHAR: Open Payments
NPI 1831733252 · INDIANA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$737 in 40 payments from 11 companies in 2025. Trend: 2023 $1,607 · 2024 $315 · 2025 $737
Food & beverage: $737
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 12 | $189 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $108 |
| Otsuka America Pharmaceutical, Inc. | 6 | $107 |
| Vanda Pharmaceuticals Inc. | 4 | $100 |
| Neurocrine BioSciences, Inc. | 4 | $68 |
| Janssen Pharmaceuticals, Inc | 3 | $49 |
| Lundbeck LLC | 2 | $41 |
| Sage Therapeutics, LLC | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| E.R. Squibb & Sons, L.L.C. | 1 | $18 |
Products named: UZEDY, CAPLYTA, REXULTI, AUSTEDO XR, FANAPT, INGREZZA, ABILIFY MAINTENA, INVEGA SUSTENNA.
Industry payments across PA — which companies pay providers there.
